Form 4: Pieris Pharmaceuticals Director Acquires Series F Preferred Stock
SEC Form 4 Filing
Director James A. Geraghty purchased one share of Series F Preferred Stock in Pieris Pharmaceuticals on August 7, 2024.
Summary
- On August 7, 2024, James A. Geraghty, a director of Pieris Pharmaceuticals, acquired one share of Series F Preferred Stock from the company for $1.00.
- The Series F Preferred Stock grants the holder 25,000,000 votes and the right to vote with common stockholders on specific proposals outlined in the Certificate of Designation of Series F Preferred Stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This transaction indicates a director's investment in the company's preferred stock.
Stakeholder Impact
- The purchase of preferred stock by a director could be viewed positively by shareholders as it demonstrates confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 08/07/2024 | Director James A. Geraghty purchased one share of Series F Preferred Stock for $1.00. |
| 10/28/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.